The Risks of Drug Discontinuation in RA Patients

There were significantly higher rates of major adverse cardiac events, ACS acute coronary syndromes, strokes, serious infections, herpes zoster, liver disease, and suicide. The discontinuation rate was higher with Abatassip, Inflict Somab, Golimimab, and Serdylismab. But lower on Tophocilismab or Toximab and Baracitinib.